Brought to you by Investec Switzerland.
Reuters reports that an investigation is taking place after an anonymous whistle-blower accused Novartis of paying bribes through a consulting firm to secure business advantages in Turkey worth around $85 million, citing an email seen by a reporter.
The benefits are reported to include getting medicines added to lists of drugs approved for prescription in government-run hospitals and avoiding price cuts.
Novartis says it is investigating the allegations. Novartis spokesman Eric Althoff confirmed to Bloomberg News that the facts in the Reuters article are correct and is investigating allegations.